Meet Jonathan Phillips, Intellia Senior Director, Toxicology. Jonathan recalls what it was like setting up IND-enabling studies on our #RoadtotheClinic for our first in vivo development candidate, NTLA-2001 for the treatment of #ATTR. #CRISPR https://t.co/JLDXmvrBgc